Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.29 USD | +2.39% | +0.41% | -39.30% |
30/04 | Wells Fargo Cuts Price Target on Accolade to $10 From $12, Maintains Equalweight Rating | MT |
26/04 | Morgan Stanley Trims Accolade's Price Target to $12 From $13, Maintains Equal Weight Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.30% | 558M | |
+18.92% | 81.04B | |
-29.48% | 68.93B | |
+9.65% | 29.59B | |
-0.14% | 17.24B | |
-9.30% | 16.99B | |
+0.20% | 15.12B | |
+5.25% | 13.09B | |
+68.96% | 12B | |
-2.88% | 11.94B |
- Stock Market
- Equities
- ACCD Stock
- News Accolade, Inc.
- Transcript : Accolade, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07